Skip to main content
Erschienen in: Der Nervenarzt 3/2018

08.02.2018 | Demenz | CME

Biomarker-basierte Diagnostik der Alzheimer-Krankheit

Konzept der „suspected non-Alzheimer pathology“

verfasst von: PD Dr. K. Fliessbach, Prof. Dr. A. Schneider

Erschienen in: Der Nervenarzt | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Zusammenfassung

Im Bereich der prodromalen Alzheimer-Krankheit nimmt die Biomarker-basierte Diagnostik mittlerweile einen zunehmenden Stellenwert ein. Unklare Biomarker-Konstellationen, wie z. B. die „suspected non-Alzheimer pathology“ (SNAP), können zu diagnostischen und prognostischen Unsicherheiten führen. Eine Anwendung der Biomarker-basierten Forschungskriterien in der klinischen Routine ist deshalb nicht unproblematisch. Trotz z. T. widersprüchlicher Befunde scheint es weitgehend gesichert, dass die Biomarker-Konstellation einer SNAP zumindest bei Patienten mit leichtem kognitivem Defizit (MCI) ein erhöhtes Progressionsrisiko zur Demenz anzeigt. Im Beitrag werden die prognostischen Implikationen eines SNAP-Befundes erörtert und anhand der SNAP diagnostische und prognostische Probleme der Biomarker-basierten Diagnosekriterien aufgezeigt.
Literatur
1.
Zurück zum Zitat Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid beta-peptide. Nat Rev Mol Cell Biol 8(2):101–112CrossRefPubMed Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid beta-peptide. Nat Rev Mol Cell Biol 8(2):101–112CrossRefPubMed
2.
Zurück zum Zitat Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ et al (2012) Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 71(5):362–381CrossRefPubMedPubMedCentral Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ et al (2012) Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 71(5):362–381CrossRefPubMedPubMedCentral
3.
4.
Zurück zum Zitat Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297(5580):353–356CrossRefPubMed Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297(5580):353–356CrossRefPubMed
5.
Zurück zum Zitat Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC et al (2012) Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med 367(9):795–804CrossRefPubMedPubMedCentral Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC et al (2012) Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med 367(9):795–804CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Jack CR Jr., Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS et al (2013) Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 12(2):207–216CrossRefPubMedPubMedCentral Jack CR Jr., Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS et al (2013) Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 12(2):207–216CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Sutphen CL, Jasielec MS, Shah AR, Macy EM, Xiong C, Vlassenko AG et al (2015) Longitudinal cerebrospinal fluid biomarker changes in preclinical Alzheimer disease during middle age. JAMA Neurol 72(9):1029–1042CrossRefPubMedPubMedCentral Sutphen CL, Jasielec MS, Shah AR, Macy EM, Xiong C, Vlassenko AG et al (2015) Longitudinal cerebrospinal fluid biomarker changes in preclinical Alzheimer disease during middle age. JAMA Neurol 72(9):1029–1042CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Jack CR Jr., Vemuri P, Wiste HJ, Weigand SD, Aisen PS, Trojanowski JQ et al (2011) Evidence for ordering of Alzheimer disease biomarkers. Arch Neurol 68(12):1526–1535CrossRefPubMedPubMedCentral Jack CR Jr., Vemuri P, Wiste HJ, Weigand SD, Aisen PS, Trojanowski JQ et al (2011) Evidence for ordering of Alzheimer disease biomarkers. Arch Neurol 68(12):1526–1535CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Ng KP, Pascoal TA, Mathotaarachchi S, Therriault J, Kang MS, Shin M et al (2017) Monoamine oxidase B inhibitor, selegiline, reduces 18 F‑THK5351 uptake in the human brain. Alzheimers Res Ther 9(1):25CrossRefPubMedPubMedCentral Ng KP, Pascoal TA, Mathotaarachchi S, Therriault J, Kang MS, Shin M et al (2017) Monoamine oxidase B inhibitor, selegiline, reduces 18 F‑THK5351 uptake in the human brain. Alzheimers Res Ther 9(1):25CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Jack CR Jr., Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW et al (2010) Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet 9(1):119–128CrossRefPubMedPubMedCentral Jack CR Jr., Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW et al (2010) Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet 9(1):119–128CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K et al (2014) Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol 13(6):614–629CrossRefPubMed Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K et al (2014) Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol 13(6):614–629CrossRefPubMed
12.
Zurück zum Zitat Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM et al (2011) Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7(3):280–292CrossRefPubMedPubMedCentral Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM et al (2011) Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7(3):280–292CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC et al (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7(3):270–279CrossRefPubMedPubMedCentral Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC et al (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7(3):270–279CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr., Kawas CH et al (2011) The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7(3):263–269CrossRefPubMedPubMedCentral McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr., Kawas CH et al (2011) The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7(3):263–269CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Jack CR Jr., Knopman DS, Weigand SD, Wiste HJ, Vemuri P, Lowe V et al (2012) An operational approach to National Institute on Aging-Alzheimer’s Association criteria for preclinical Alzheimer disease. Ann Neurol 71(6):765–775CrossRefPubMedPubMedCentral Jack CR Jr., Knopman DS, Weigand SD, Wiste HJ, Vemuri P, Lowe V et al (2012) An operational approach to National Institute on Aging-Alzheimer’s Association criteria for preclinical Alzheimer disease. Ann Neurol 71(6):765–775CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Jack CR Jr., Therneau TM, Wiste HJ, Weigand SD, Knopman DS, Lowe VJ et al (2016) Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study. Lancet Neurol 15(1):56–64CrossRefPubMed Jack CR Jr., Therneau TM, Wiste HJ, Weigand SD, Knopman DS, Lowe VJ et al (2016) Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study. Lancet Neurol 15(1):56–64CrossRefPubMed
17.
Zurück zum Zitat Knopman DS, Jack CR Jr., Wiste HJ, Weigand SD, Vemuri P, Lowe V et al (2012) Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology 78(20):1576–1582CrossRefPubMedPubMedCentral Knopman DS, Jack CR Jr., Wiste HJ, Weigand SD, Vemuri P, Lowe V et al (2012) Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology 78(20):1576–1582CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Mormino EC, Betensky RA, Hedden T, Schultz AP, Ward A, Huijbers W et al (2014) Amyloid and APOE epsilon4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology 82(20):1760–1767CrossRefPubMedPubMedCentral Mormino EC, Betensky RA, Hedden T, Schultz AP, Ward A, Huijbers W et al (2014) Amyloid and APOE epsilon4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology 82(20):1760–1767CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Jack CR Jr., Knopman DS, Chetelat G, Dickson D, Fagan AM, Frisoni GB et al (2016) Suspected non-Alzheimer disease pathophysiology – concept and controversy. Nat Rev Neurol 12(2):117–124CrossRefPubMedPubMedCentral Jack CR Jr., Knopman DS, Chetelat G, Dickson D, Fagan AM, Frisoni GB et al (2016) Suspected non-Alzheimer disease pathophysiology – concept and controversy. Nat Rev Neurol 12(2):117–124CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Gordon BA, Blazey T, Su Y, Fagan AM, Holtzman DM, Morris JC et al (2016) Longitudinal beta-amyloid deposition and hippocampal volume in preclinical Alzheimer disease and suspected non-Alzheimer disease pathophysiology. JAMA Neurol 73(10):1192–1200CrossRefPubMedPubMedCentral Gordon BA, Blazey T, Su Y, Fagan AM, Holtzman DM, Morris JC et al (2016) Longitudinal beta-amyloid deposition and hippocampal volume in preclinical Alzheimer disease and suspected non-Alzheimer disease pathophysiology. JAMA Neurol 73(10):1192–1200CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Burnham SC, Bourgeat P, Dore V, Savage G, Brown B, Laws S et al (2016) Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer’s disease pathophysiology (SNAP) or Alzheimer’s disease pathology: a longitudinal study. Lancet Neurol 15(10):1044–1053CrossRefPubMed Burnham SC, Bourgeat P, Dore V, Savage G, Brown B, Laws S et al (2016) Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer’s disease pathophysiology (SNAP) or Alzheimer’s disease pathology: a longitudinal study. Lancet Neurol 15(10):1044–1053CrossRefPubMed
22.
Zurück zum Zitat Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K (2006) Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 112(4):389–404CrossRefPubMedPubMedCentral Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K (2006) Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 112(4):389–404CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Pontecorvo MJ, Devous MD Sr., Navitsky M, Lu M, Salloway S, Schaerf FW et al (2017) Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. Brain 140(3):748–763PubMedPubMedCentral Pontecorvo MJ, Devous MD Sr., Navitsky M, Lu M, Salloway S, Schaerf FW et al (2017) Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. Brain 140(3):748–763PubMedPubMedCentral
24.
Zurück zum Zitat Braak H, Thal DR, Ghebremedhin E, Del Tredici K (2011) Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol 70(11):960–969CrossRefPubMed Braak H, Thal DR, Ghebremedhin E, Del Tredici K (2011) Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol 70(11):960–969CrossRefPubMed
25.
Zurück zum Zitat Knopman DS (2014) beta-Amyloidosis and neurodegeneration in Alzheimer disease: who’s on first? Neurology 82(20):1756–1757CrossRefPubMed Knopman DS (2014) beta-Amyloidosis and neurodegeneration in Alzheimer disease: who’s on first? Neurology 82(20):1756–1757CrossRefPubMed
26.
Zurück zum Zitat Brier MR, Gordon B, Friedrichsen K, McCarthy J, Stern A, Christensen J et al (2016) Tau and Abeta imaging, CSF measures, and cognition in Alzheimer’s disease. Sci Transl Med 8(338):338ra66CrossRefPubMedPubMedCentral Brier MR, Gordon B, Friedrichsen K, McCarthy J, Stern A, Christensen J et al (2016) Tau and Abeta imaging, CSF measures, and cognition in Alzheimer’s disease. Sci Transl Med 8(338):338ra66CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Cho H, Choi JY, Hwang MS, Kim YJ, Lee HM, Lee HS et al (2016) In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum. Ann Neurol 80(2):247–258CrossRefPubMed Cho H, Choi JY, Hwang MS, Kim YJ, Lee HM, Lee HS et al (2016) In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum. Ann Neurol 80(2):247–258CrossRefPubMed
28.
Zurück zum Zitat Scholl M, Lockhart SN, Schonhaut DR, O’Neil JP, Janabi M, Ossenkoppele R et al (2016) PET imaging of tau deposition in the aging human brain. Neuron 89(5):971–982CrossRefPubMedPubMedCentral Scholl M, Lockhart SN, Schonhaut DR, O’Neil JP, Janabi M, Ossenkoppele R et al (2016) PET imaging of tau deposition in the aging human brain. Neuron 89(5):971–982CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Vos SJ, Verhey F, Frolich L, Kornhuber J, Wiltfang J, Maier W et al (2015) Prevalence and prognosis of Alzheimer’s disease at the mild cognitive impairment stage. Brain 138(Pt 5):1327–1338CrossRefPubMedPubMedCentral Vos SJ, Verhey F, Frolich L, Kornhuber J, Wiltfang J, Maier W et al (2015) Prevalence and prognosis of Alzheimer’s disease at the mild cognitive impairment stage. Brain 138(Pt 5):1327–1338CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Vos SJ, Gordon BA, Su Y, Visser PJ, Holtzman DM, Morris JC et al (2016) NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers. Neurobiol Aging 44:1–8CrossRefPubMedPubMedCentral Vos SJ, Gordon BA, Su Y, Visser PJ, Holtzman DM, Morris JC et al (2016) NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers. Neurobiol Aging 44:1–8CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Wisse LE, Butala N, Das SR, Davatzikos C, Dickerson BC, Vaishnavi SN et al (2015) Suspected non-AD pathology in mild cognitive impairment. Neurobiol Aging 36(12):3152–3162CrossRefPubMedPubMedCentral Wisse LE, Butala N, Das SR, Davatzikos C, Dickerson BC, Vaishnavi SN et al (2015) Suspected non-AD pathology in mild cognitive impairment. Neurobiol Aging 36(12):3152–3162CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Mormino EC, Papp KV, Rentz DM, Schultz AP, LaPoint M, Amariglio R et al (2016) Heterogeneity in suspected non-Alzheimer disease pathophysiology among clinically normal older individuals. JAMA Neurol 73(10):1185–1191CrossRefPubMedPubMedCentral Mormino EC, Papp KV, Rentz DM, Schultz AP, LaPoint M, Amariglio R et al (2016) Heterogeneity in suspected non-Alzheimer disease pathophysiology among clinically normal older individuals. JAMA Neurol 73(10):1185–1191CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Caroli A, Prestia A, Galluzzi S, Ferrari C, van der Flier WM, Ossenkoppele R et al (2015) Mild cognitive impairment with suspected nonamyloid pathology (SNAP): prediction of progression. Neurology 84(5):508–515CrossRefPubMedPubMedCentral Caroli A, Prestia A, Galluzzi S, Ferrari C, van der Flier WM, Ossenkoppele R et al (2015) Mild cognitive impairment with suspected nonamyloid pathology (SNAP): prediction of progression. Neurology 84(5):508–515CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Jack CR Jr., Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB et al (2016) A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology 87(5):539–547CrossRefPubMedPubMedCentral Jack CR Jr., Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB et al (2016) A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology 87(5):539–547CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Zhao YTD, Lopez OL, Cohen AD, Price J, Mathis C, Klunk WE, Snitz BE (2016) Beta-amyloid deposition and suspected non-alzheimer’s pathophysiology (snap) exhibit different decline patterns among cognitive domains. Alzheimers Dement 12(7):P572–P3CrossRef Zhao YTD, Lopez OL, Cohen AD, Price J, Mathis C, Klunk WE, Snitz BE (2016) Beta-amyloid deposition and suspected non-alzheimer’s pathophysiology (snap) exhibit different decline patterns among cognitive domains. Alzheimers Dement 12(7):P572–P3CrossRef
36.
Zurück zum Zitat Petersen RC, Aisen P, Boeve BF, Geda YE, Ivnik RJ, Knopman DS et al (2013) Mild cognitive impairment due to Alzheimer disease in the community. Ann Neurol 74(2):199–208PubMedPubMedCentral Petersen RC, Aisen P, Boeve BF, Geda YE, Ivnik RJ, Knopman DS et al (2013) Mild cognitive impairment due to Alzheimer disease in the community. Ann Neurol 74(2):199–208PubMedPubMedCentral
37.
Zurück zum Zitat Prestia A, Caroli A, van der Flier WM, Ossenkoppele R, Van Berckel B, Barkhof F et al (2013) Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. Neurology 80(11):1048–1056CrossRefPubMed Prestia A, Caroli A, van der Flier WM, Ossenkoppele R, Van Berckel B, Barkhof F et al (2013) Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. Neurology 80(11):1048–1056CrossRefPubMed
38.
Zurück zum Zitat Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M et al (2014) Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med 370(4):322–333CrossRefPubMedPubMedCentral Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M et al (2014) Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med 370(4):322–333CrossRefPubMedPubMedCentral
Metadaten
Titel
Biomarker-basierte Diagnostik der Alzheimer-Krankheit
Konzept der „suspected non-Alzheimer pathology“
verfasst von
PD Dr. K. Fliessbach
Prof. Dr. A. Schneider
Publikationsdatum
08.02.2018
Verlag
Springer Medizin
Erschienen in
Der Nervenarzt / Ausgabe 3/2018
Print ISSN: 0028-2804
Elektronische ISSN: 1433-0407
DOI
https://doi.org/10.1007/s00115-018-0488-2

Weitere Artikel der Ausgabe 3/2018

Der Nervenarzt 3/2018 Zur Ausgabe

Mitteilungen der DGN

Mitteilungen der DGN